SOURCE: GCPSiro

February 21, 2006 06:00 ET

GCPSiro (USA) and SIRO Clinpharm (India) Announce Global Expansion to Deliver Comprehensive Clinical Trial Services to US Pharma and Biotechs

PRINCETON, NJ and MUMBAI, INDIA -- (MARKET WIRE) -- February 21, 2006 -- Siro Clinpharm Pvt. Ltd. announced today the next step in the global expansion of its CRO business. Siro Clinpharm has entered into a formal agreement with GCPSiro to offer a US Clinical Research Organization specializing in the management of late-stage clinical studies using proven capabilities in India.

Conducting clinical trials in India offers a number of advantages, including a relatively lower trial cost per patient compared to the US and Europe, access to an extensive pool of patients in a range of therapeutic areas, knowledgeable investigators, and above all the ability to accelerate patient enrollment.

Dr. Mark Bradshaw, Ph.D., President of GCPSiro, commented: "India offers a widely accepted and compelling solution to pharma's urgent need to reduce clinical trial recruitment time and overall R&D costs. US pharmaceutical and biotech companies without an Indian presence have not had effective access to these capabilities. GCPSiro, with offices in Princeton, NJ, and San Jose, CA, now offers US-based pharmaceutical and biotech companies immediate, managed access to the best and most established global clinical trial capabilities in India. Pharma and biotech companies can now utilize Indian clinical trial investigators, patient populations, and other expert resources for their global registration trials without adding overheads or internal project management costs. GCPSiro provides the necessary US-based project management, client liaison and other direct drug development support services."

Dr. Gautam Daftary, M.D., founder of Siro Clinpharm, commented: "The highest level of scientific integrity, world-class quality, and a focus on client service are the cornerstones of Siro and GCPSiro. Led by a senior US pharmaceutical executive with significant first-hand experienced in India, GCPSiro guarantees compliance with the principles of Good Clinical Practice (GCP) and full US and India regulatory requirements."

GCPSiro has also established a group of top level US and European partner companies and consultants to offer coordination of full clinical development consulting and operational services to clients who need a broader level of support. Services include US regulatory consulting, clinical trial management and monitoring, data and statistical services, and full US and European regulatory submission capabilities. For more information on GCPSiro, visit www.gcpsiro.com.

About SIRO Clinpharm

SIRO Clinpharm Pvt. Ltd. is a leading full-service contract Clinical Research Organization (CRO) providing clinical development solutions to support Phase I - IV clinical trials in India. Armed with strong clinical project management, data management and biometrics capabilities, SIRO is successfully managing contracts for some of the leading global pharmaceutical companies. SIRO has a 10-year track record delivering pivotal data that has led to numerous FDA and EU approvals. In October 2005, SIRO was selected from among 60 companies as the 2005 winner of Proximare's "Best Indian CRO Award" in Clinical Research (Phase I - IV). For more information on SIRO Clinpharm, visit www.siroindia.com.

Contact Information

  • US - Mark Bradshaw
    GCPSiro
    49 B, Palmer Square West
    Princeton, NJ, USA
    Tel: +1 609 924-4669
    Email: Email Contact

    India - Chetan Tamhankar
    SIRO Clinpharm Pvt Ltd
    106, Lady Ratan Tata Medical Research Centre
    31, M. Karve Road, Mumbai - 400021
    Tel: +91 22- 2284 4011
    Email: Email Contact